N/A N=102 Iron Parameters in Non-anemic First Trimester Gravidas
Iron Deficiency (Without Anemia) · Pregnancy
Primary: Percent of Non-anemic Patients With Iron Deficiency Stratified by Gravidity — 9; 3; 6; 38 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=15 Iron Indices and Intravenous Ferumoxytol: Time to Steady State
Iron Deficiency Anemia
Primary: Number of Weeks Until Transferrin Saturation (TSAT) and Ferritin Stabilize — 2 weeks
Phase 4 N=243 An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)
Thalassemia, Non-transfusional-dependent Thalassemia (NTDT), Myeloplastic Dysplasia (MDS), Other Anemia
Primary: Percentage of Participants With Cardiac and Liver Iron Overload. — 10; 22; 4; 0 Percentage of participants
Phase 3 N=102 Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients
Heart Transplant Recipients
Primary: Peak Oxygen Consumption — 23.9; 22.0 ml/kg/min
N/A N=142 Massive Iron Deposit Assessment
Iron Overload · Excessive Body Iron Burden
Primary: Hepatic Iron Content in the Liver Using Liver Biopsy — 19.8 mcg
Phase 3 N=51 Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia
Anemia · Iron Deficiency Anemia
Primary: Feasibility of Enrolling Patients in the Trial — 85 participants
N/A N=77 Measurements of Body Iron Excretion of Healthy Adults
Healthy
Primary: Rate of Iron Excretion. — 1.07; 1.69; 1.08 milligrams per day — p=< 0.05
Phase 4 N=20 Iron Bioavailability of Fortified Oat Drink
Iron Absorption
Primary: Percent Iron Absorption — 7.14; 5.65 percentage of Iron absorbed
N/A N=197 Iron Depletion and Replacement in Blood Donors
Anemia
Primary: Number of Participants With Adherence to Iron Replacement Therapy at Subsequent Donation — 116; 17 Participants
N/A N=79 Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality
Iron Deficiency
Primary: 51-Chromium 24-hour Post-transfusion RBC Recovery of Units — 1.6; -0.4 percentage change
N/A N=56 Evaluation of Natureheme-iron on Iron Absorption Effect and Anti-oxidation Functions
Anemia
Primary: The Hemoglobin of the Subjects at Baseline and 6 Weeks — 0.38; 0.29; 0.57 g/dl
Phase 2 N=149 Intravenous Iron Supplement for Iron Deficiency in Patients With Severe Aortic Stenosis
Severe Aortic Stenosis · Iron-deficiency
Primary: Submaximal Exercise Test — 375; 384 meters
Phase 2 N=12 Intravenous Iron Metabolism in Restless Legs Syndrome
Restless Legs
Primary: Duration Off Treatment — 6; 3; 2; 0 participants
Phase 2 N=200 Efficacy of Enteral Iron Supplementation in Critical Illness
Anemic, Critically Ill Patients
Primary: Hematocrit — 29.3; 29.1; 28.6; 28.2 percentage of RBC in blood
Phase 3 N=402 Sub-clinical Inflammation and Iron Supplementation
Anemia
Primary: Haemoglobin Level — 88.3; 89.2; 88.4; 89.6 g/L — p=<0.05
N/A N=60 Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
Chronic Kidney Disease · Iron Deficiency · Anemia
Primary: Change in Ferritin From Baseline to End of Treatment — 60; 30 percentage of change from baseline
Phase 4 N=88 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate
Ulcerative Colitis · Crohn's Disease
Primary: Mean Change in Haemoglobin Concentration. — 1.22; 1.30 g/dl — p=0.23
N/A N=223 Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study
Iron-deficiency Anemia · Iron-deficiency
Primary: Haemoglobin Level — 11.35; 12.28 g/dL — p=0.025
Phase 2 N=74 Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women
Pregnancy
Primary: Percentage of Women Who Achieve Anemia Correction After a Single Dose of 1000mg of Low Molecular Weight Iron Dextran(INfeD). — 35; 11 Participants
Phase 2 N=49 Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
Iron Deficiency Anemia
Primary: Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane) — -11.90; -1.06; -12.37; -11.14 mg
Phase 3 N=270 A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.
Haematopoiesis
Primary: Change From Baseline in Hemoglobin (Hb) After 8 Weeks of Treatment in Each Ferrous Bisglycinate Chelate Group (1 Tablet Daily and 2 Tablets Daily) — 2.6; 2.8 Gram per…
N/A N=16 Iron Bioavailability From MyPyramid Menus
Nonheme Iron Absorption
Primary: Nonheme Iron Absorption — 2.31 percentage of nonheme Iron absorbed
Phase 4 N=57 IV Iron Safety: Evaluation of Iron Species in Healthy Subjects
Anemia
Primary: Non-transferrin Bound Iron — 56230; 61250 ppb x hours
Phase 3 N=1,512 Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)
Iron Deficiency Anaemia · Iron Deficiency Anemia
Primary: Change in Hemoglobin (Hb) From Baseline to Week 8 — 2.49; 2.49 g/dL
Phase 4 N=154 Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors
Fatigue · Iron Deficiency
Primary: Level of Fatigue Before and After Iron Treatment/Placebo, Using a 10 Point Visual Analogue Scale. — 3.4; 3.5 centimeter — p=0.69
Phase 4 N=1,025 Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron
Iron Deficiency Anemia (IDA)
Primary: Multidimensional Assessment of Fatigue (MAF) Scores — -8.8; -8.1 units on a scale
N/A N=25 Investigation of Iron Uptake From Micronutrient Fortified Powder Versus From Tailored Control in Milk
Growth and Development
Primary: Fractional Iron Absorption — 2.08; 1.25 % Iron Absorbed — p=0.0944
Phase 4 N=80 Intravenous Versus Oral Iron in Late Pregnancy: Results of Treatment
Anemia · Pregnancy Complications
Primary: Serum Ferritin Level — 136.1; 28.3 µg/dL
Phase 3 N=1,538 Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease
Iron Deficiency Anaemia · Iron Deficiency Anemia · Chronic Kidney Disease
Primary: Change in Hemoglobin (Hb) From Baseline to Week 8 — 1.22; 1.14 g/dL
Phase 3 N=225 Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure
Chronic Heart Failure
Primary: Change in Peak VO2 (ml/Min) (VO2 =Oxygen Consumption) — 28.04; 3.90 mL/min — p=0.4570